UNITAID approach to working in markets to improve public health


Published on

Presentation with the occasion of the Technical Briefing at World Halth Assembly, Geneva, 18 May 2011

Published in: Health & Medicine, Education
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

UNITAID approach to working in markets to improve public health

  1. 1. UNITAID approach to working in markets to improve public health Technical Briefing World Health Assembly, Geneva 18 May, 2011 Brenda Waning
  2. 2. Session Agenda <ul><li>Brief overview of UNITAID: why and how UNITAID works through markets to improve public health </li></ul><ul><li>Key highlights of UNITAID’s portfolio to date: proof of concept that market approaches work </li></ul><ul><li>New opportunities for market interventions to improve health </li></ul><ul><li>Trends in organizations moving to adopt market approaches: presentations from other stakeholders </li></ul>
  3. 3. UNITAID: a WHO Partnership moving markets Partners Working towards the common goal of expanding access to health <ul><li>Est. 2006: Innovative finance mechanism based largely on air tax levies from north & south </li></ul><ul><li>Geneva-based </li></ul><ul><li>secretariat: no in-country offices – work with partners </li></ul><ul><li>First and only UN organization to work exclusively through markets to improve public health </li></ul><ul><ul><li>HIV/AIDS, TB, malaria </li></ul></ul>
  4. 4. UNITAID Goal Healthy markets, healthy people UNITAID aims to promote “healthy”, dynamic market conditions whereby manufacturers have incentives to invest and innovate , while at the same time supply quality public health products at affordable prices and in acceptable formulations that enable the maximum number of people to access them.
  5. 5. What is a market?
  6. 6. Market impact framework UNITAID Intervention example: 2 nd line ARV market
  7. 7. How UNITAID intervenes <ul><ul><li>UNITAID’s role depends upon the particular circumstances in a given market: </li></ul></ul><ul><li>Market catalyst: identifying and facilitating adoption and uptake of new and/or superior public health products; </li></ul><ul><li>Market creator: providing incentives for manufacturers to produce otherwise unattractive products with low demand that yield little profit but substantial public health benefit to those in need; and </li></ul><ul><li>Market “fixer”: addressing severe market inefficiencies (e.g. grossly inaccurate demand forecasts and excessive transaction costs) that contribute to low access to quality-assured public health products. </li></ul>
  8. 8. UNITAID examples (a few) <ul><li>Market catalyst: </li></ul><ul><li>Second-line ARV (& tenofovir) programs </li></ul><ul><li>Expand TB (diagnostic line probe assay) </li></ul><ul><li>Market creator: </li></ul><ul><li>Paediatric programs for HIV/AIDS & TB </li></ul><ul><li>Affordable Medicines Facility for Malaria (AMFm) </li></ul><ul><li>Market &quot;fixer&quot;: </li></ul><ul><ul><ul><li>WHO Prequalification of Medicines Programme </li></ul></ul></ul><ul><ul><ul><li>Medicines patent pool </li></ul></ul></ul><ul><ul><ul><li>Strategic rotating stockpile for TB medicines </li></ul></ul></ul><ul><ul><ul><li>ACT Forecasting </li></ul></ul></ul><ul><ul><ul><li>Market intelligence systems </li></ul></ul></ul>
  9. 9. Market intelligence: the GPS of market interventions Used to locate &quot;global positions&quot; around interventions before & after implementation UNITAID accounts for > 90% market for paediatric ARVs in fixed-dose combination form, 2009* 90% pediatric & adult 1 st line ARVs made by Indian generic producers, 2008 *
  10. 10. New opportunities: the Decade of Diagnostics <ul><li>Unprecedented innovation in diagnostics technology </li></ul><ul><ul><li>Better chemistry, simpler to use, more affordable </li></ul></ul><ul><ul><li>Finally will be able to bring diagnostics to people and regions previously underserved </li></ul></ul><ul><li>Xpert MTB </li></ul><ul><ul><li>Dramatic breakthrough in lab-based tuberculosis diagnostic technology </li></ul></ul><ul><li>Malaria Rapid Diagnostic Tests </li></ul><ul><ul><li>From labs (microscopes) to homes (disposable Point of Care tests) </li></ul></ul><ul><li>HIV CD4 and Viral Load </li></ul><ul><ul><li>From central labs to clinics (Point of Care tests) </li></ul></ul>
  11. 11. CD4 Product Pipeline*
  12. 12. Viral Load & EID Product Pipeline*
  13. 13. UNITAID is one of several players working to keep markets in balance to improve public health <ul><ul><li>UNITAID showed proof of concept: market interventions have substantial, long term impact far beyond country recipients </li></ul></ul><ul><ul><li>Many others now adopting market approaches: coordination & collaboration to leverage relative strengths & maximize use of resources towards achieving collective public health goals </li></ul></ul>
  14. 14. <ul><li>Thank you </li></ul><ul><li>Contact Information: </li></ul><ul><li>Brenda Waning </li></ul><ul><li>Coordinator, Market Dynamics </li></ul><ul><li>WHO/UNITAID </li></ul><ul><li>Email: [email_address] </li></ul>